Home › Triple-Negative Breast Cancer › New York › Syracuse
Triple-Negative Breast Cancer clinical trials in Syracuse, NY
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Syracuse (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- SUNY Upstate Medical University, Syracuse
- Hematology Oncology Associates of Central New York, PC, East Syracuse · 4 mi away
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
RecruitingPhase 2
- SUNY Upstate Medical University, Syracuse
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Local Institution - 1037, Syracuse
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Syracuse
- Non-Small Cell Lung Cancer15 studies
- Cancer (all types)9 studies
- Prostate Cancer9 studies
- Non-Muscle Invasive Bladder Cancer8 studies
- Ovarian Cancer7 studies
- Endometrial Cancer7 studies
- Obesity6 studies
- Lung Cancer6 studies
- Colorectal Cancer5 studies
- Macular Degeneration5 studies
- Acute Myeloid Leukemia5 studies
- Type 2 Diabetes5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.